Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy

Figure 5

The probabilistic results of the incremental cost-effectiveness difference. The XELOX, S-1, and surgery-only strategies were compared. The y-axis represents the incremental costs. The x-axis represents the incremental QALYs gained. The ellipses surround 95% of the estimates. The dots below the ICER threshold (the oblique lines) reflect simulations in which the cost per additional QALY gained for the XELOX strategy was below the ICER threshold.

Back to article page